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Through exome sequencing we identified six individuals with biallelic loss-of-function 
mutations in TRIP13. All six developed Wilms tumor. Constitutional mosaic aneuploidies, 
microcephaly, developmental delay and seizures, which are features of mosaic 
variegated aneuploidy (MVA) syndrome1,2, were more variably present. Through 
functional studies we show that TRIP13-mutant patient cells have no detectable TRIP13, 
and have substantial impairment of the spindle assembly checkpoint (SAC) leading to a 
high rate of chromosome missegregation. Accurate segregations as well as SAC 
proficiency are rescued by restoring TRIP13 function. Individuals with biallelic TRIP13 or 
BUB1B mutations have a high risk of embryonal tumors3, and here we show that their 
cells show severe SAC impairment. MVA due to biallelic CEP57 mutations4, or of 
unknown cause, is not associated with embryonal tumors and their cells show minimal 
SAC deficiency. These data suggest it may be the underlying mechanism leading to 
aneuploidy, rather than aneuploidy per se, that causes the high cancer risk associated 
with MVA syndrome, and provide insights into the complex relationships between 
aneuploidy and carcinogenesis.  
 
Accurate chromosome segregation during cell division is required to maintain the correct 
number of chromosomes in cells. Errors of chromosome segregation can lead to aneuploidy, a 
term that describes cells with loss or gain of one or more chromosomes. Aneuploidy is an 
important cause of human disease, implicated in diverse pathologies, including recurrent 
miscarriage, infertility, developmental disorders and cancer5-7. Many biological processes, 
including spindle assembly, chromatid-spindle attachment, attachment error-correction, and the 
spindle assembly checkpoint (SAC) are involved in ensuring chromosome segregation proceeds 
flawlessly and that aneuploidy is prevented6,8.  
 
Rare individuals with constitutional mosaic aneuploidies involving varying chromosomes are 
well documented1,2. Affected individuals often have other clinical features such as microcephaly, 
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developmental delay and various congenital abnormalities, and the term ‘mosaic variegated 
aneuploidy (MVA)’is used to describe this condition1-3. Cancer predisposition is one of the most 
important associations of MVA, with substantial increased risk of childhood malignancies, 
particularly Wilms tumor and rhabdomyosarcoma3,9,10.  
 
We have been studying this rare condition for over a decade. We previously reported biallelic 
mutations in the spindle assembly checkpoint gene BUB1B as a cause of MVA and childhood 
cancer3. To date we have identified 14 individuals with biallelic BUB1B mutations. More recently 
we identified biallelic mutations in CEP57, which encodes a centrosomal protein involved in 
kinetochore attachment, in four individuals with MVA, none of whom have developed cancer4. 
Together these two genes only account for a proportion of MVA cases.  
 
To identify additional MVA genes we undertook exome sequencing in 43 individuals from 20 
families, including 21 probands with MVA (Supplementary Table 1). We generated exome data 
using Illumina exome capture assays and called variants using the OpEx pipeline as previously 
described11,12. We performed two analyses to prioritize variants for further evaluation. We 
undertook an individual proband analysis to identify genes with two rare variants, as MVA is a 
recessively inherited condition. We also identified genes with protein truncating variants (PTVs) 
present in more than one proband, using the PTV prioritization method4,12.  
 
We identified the homozygous stop-gain mutation TRIP13 c.1060C>T_p.Arg354X in three 
probands (ID_0319, ID_0644, ID_7054) (Table 1, Supplementary Fig. 1). The mutation leads to 
nonsense-mediated mRNA decay (Supplementary Fig. 2) and absence of detectable TRIP13 
protein (Supplementary Fig. 3). Protein expressed from exogenous cDNA was degraded by the 
proteasome (Supplementary Fig. 4), suggesting that if any residual mRNA remains and is 
translated, mutant TRIP13 protein will not be expressed.  
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The three individuals had been independently recruited and there was no known relationship 
between them, but they were from families of Asian origin. Interestingly, all three had Wilms 
tumor. To further explore the association of TRIP13 and Wilms tumor we performed exome 
sequencing in 11 UK individuals of reported Asian origin with Wilms tumor. Two, ID_0649 and 
ID_6112, were also homozygous for TRIP13 c.1060C>T_p.Arg354X (Table 1 and 
Supplementary Fig. 1). ID_0649 had been noted to have premature chromatid separation, but 
no mosaic aneuploidies in lymphocytes. No constitutional karyotype in ID_6112 has been 
performed, but the tumor karyotype was reported to be normal. Of note, the sister of ID_6112 
died at four years of age after developing a pelvic Sertoli-Leydig cell tumor and acute myeloid 
leukemia (AML). No sample is available for mutation testing, but this observation suggests 
biallelic TRIP13 mutations may also predispose to cancers other than Wilms tumor.  
 
The four available parental samples were all heterozygous for the mutation, consistent with 
recessive inheritance. The mutation is not present in the Exome Aggregation Consortium 
(ExAC) or ICR1000 series13,14, nor is it present in 11,677 other exomes we have analyzed with 
the same pipeline. Multidimensional scaling analysis strongly suggests the families originate 
from Pakistan (Supplementary Fig. 5). Exploration of the available family history suggests the 
families come from the Azad Kashmir region of Pakistan. Many Azad Kashmir families were 
given work permits for the UK in the 1960s due to the construction of the Mangla Dam, which 
led to large-scale local displacement. The incidence of Wilms tumor in this region of Pakistan is 
very high (M Rashid, personal communication). This may be related to the TRIP13 mutation we 
have identified. Evaluation of the contribution of the TRIP13 mutation to Wilms tumor in this 
population would therefore be of interest.  
 
We subsequently became aware of a Norwegian girl, ID_7679, who developed Wilms tumor at 
15 months, who is homozygous for a different truncating TRIP13 mutation. The mutation, c.697-
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1G>C, is predicted to disrupt the canonical 3’ splice-site in intron 7 of TRIP13 and a new splice-
site 2bp upstream is predicted to be used, resulting in a 2bp frameshift and premature protein 
truncation. No constitutional mosaic aneuploidies were observed in her lymphocytes.  
 
These data provide compelling genetic evidence that TRIP13 is a cancer predisposition gene. 
Biallelic loss-of-function TRIP13 mutations confer a high risk of Wilms tumor and also 
predispose to chromosome segregation dysfunction which can manifest as mosaic aneuploidies 
and/or premature chromatid separation. There were no consistent phenotypic features amongst 
the six probands, though developmental delay, microcephaly, seizures, growth retardation and 
skin pigmentation were each noted in more than one individual (Table 1 and Supplementary Fig. 
1).  
 
TRIP13 encodes a highly conserved AAA+ATPase that contributes to homologue pairing, 
synapsis and recombination during meiosis15. In mitosis, TRIP13 promotes the conversion of 
the crucial SAC effector MAD2 to an inactive conformation via interaction with p31comet 16,17. This 
has dual impact on SAC function: in prometaphase, the generation of inactive MAD2 molecules 
enables continuous replenishment of MAD2 pools that can be activated by unattached 
kinetochores, thus ensuring long-term SAC signaling. In metaphase however, when no new 
active MAD2 is generated by kinetochores, MAD2 inactivation by TRIP13 causes SAC silencing 
and allows mitotic exit18-20.  
 
We sought to examine which defective molecular processes underlie aneuploidy and 
chromosome missegregation in TRIP13-mutant patients. We first infected immortalized TRIP13-
mutant patient lymphoblasts with virus carrying H2B-mNeon to visualize chromatin. Live cell 
imaging showed that patient lymphoblasts displayed high levels of chromosome segregation 
errors such as lagging chromosomes and chromosome bridges (Fig. 1a,b). To understand how 
TRIP13 mutations cause chromosomal instability (CIN) in patient cells, we examined the fidelity 
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of the SAC, the main chromosome segregation surveillance mechanism in which TRIP13 has 
been implicated. To this end, we analyzed cells for their ability to maintain mitotic arrest after 
exposure to the spindle poison nocodazole (Fig. 1c). Control cells maintained the arrest for >2 
hours, whereas all cells from two different TRIP13-mutant patients escaped the arrest within 
one hour (Fig. 1c,d). Mitotic exit despite unattached chromosomes is indicative of a 
compromised SAC.  
 
To gain insight into the molecular defect causing SAC impairment, we analyzed SAC protein 
expression and subcellular localization. Immunofluorescence imaging of the SAC effector MAD2 
in nocodazole-treated cells showed that TRIP13-mutant patient cells recruited ~50% fewer 
molecules of MAD2 to their unattached kinetochores (Fig. 1e,f). Kinetochore levels of the MAD2 
receptor MAD1 were unaffected (Fig. 1g). Absence of TRIP13 caused increased overall p31comet 
expression and reduced overall MAD2 expression (Supplementary Fig. 6), consistent with data 
reported in TRIP13 knockout HeLa cells20.  
 
We next restored TRIP13 function by expressing GFP-TRIP13 in patient lymphoblasts using 
lentiviral delivery. Importantly, GFP-TRIP13 expression rescued the CIN as well as the SAC 
defect (Fig. 2a,b). Moreover, GFP-tagged TRIP13 p.Arg354X was unable to rescue an impaired 
SAC caused by CRISPR/Cas9-mediated knock out of the TRIP13 gene in HCT116 cells (Fig. 2c 
and Supplementary Fig. 7,8). These observations provide an explanation for the chromosome 
segregation defects observed in individuals with biallelic TRIP13 loss-of-function mutations. 
They also show that the SAC defects and resulting CIN are directly due to the loss of TRIP13 
function caused by the homozygous TRIP13 c.1060C>T_p.Arg354X mutation.  
 
TRIP13 and BUBR1 (the protein encoded by BUB1B) are close functional partners in the 
spindle assembly checkpoint15. BUBR1 is part of the anaphase inhibitory complex MCC which 
also includes MAD2, the main target of TRIP13’s remodeling activity in mitosis21. Notably, 
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severe SAC impairment was observed in TRIP13-mutant or BUB1B-mutant patient cells but not 
in cells from patients with CEP57 mutations or in whom the cause of MVA remains unclear after 
exome sequencing (Fig. 3).   
 
All six children with biallelic TRIP13 mutations developed Wilms tumor in childhood, five of 
whom were successfully treated (Table 1). Limited information is available, but there were no 
obvious distinctive histopathological features in the tumors. Individuals with biallelic BUB1B 
mutations are also at high risk of childhood embryonal tumors. In fact, all MVA cases with 
childhood solid tumors in our series have either BUB1B or TRIP13 mutations. By contrast, only 
one MVA individual in our series without mutations in BUB1B or TRIP13 has developed cancer, 
an ALL at 3 years in a child in whom the cause of MVA remains unknown10. It is therefore 
tempting to speculate that the high cancer risk may be causally related to severe impairment of 
the SAC. Irrespective of the mechanism, our findings have clinical utility indicating that BUB1B 
and TRIP13 mutation-positive individuals are at high risk of cancer and require close 
surveillance, whereas other individuals with MVA may be at lower cancer risk. 
 
The data also suggest that the mechanism generating aneuploidy in affected individuals 
determines the cancer risk, not the aneuploidy per se. If confirmed, this is an important 
distinction as there has long been a debate regarding whether aneuploidy is a cause or 
consequence of cancer5. Further studies into the biological sequelae of these rare human 
mutations may therefore provide insights into the complex relationships between aneuploidy 
and carcinogenesis. 
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Figure Legends 
 
 
Figure 1: TRIP13 loss-of-function mutations cause chromosome segregation errors and 
SAC deficiency 
(a) Representative anaphases of immortalized control (upper) and TRIP13-mutant patient 
(lower) lymphoblasts expressing H2B-mNeon, showing a lagging chromosome in the lower 
panel. 
(b) Quantification of chromosome segregation errors of lymphoblasts as visualized in (a). Each 
bar depicts the mean of 3-4 experiments ±SEM, >60 cells in total. P-values ≤ 0.05, from 
unpaired Student’s t-tests, are shown. Patient 1 cells show increased levels of chromosome 
segregation errors. 
(c) Representative images of H2B-mNeon expressing control (upper) and patient (lower) 
lymphoblasts going through mitosis (time in hours with mitotic entry at t=0.0) in the presence of 
nocodazole. Only the patient 1 cell has exited from mitosis after 1.5 hours (lower right panel). 
(d) Analysis of mitotic delay of cells as visualized in (c), indicating the cumulative percentage of 
cells that exited from mitosis as a function of time (mean of three experiments ±SEM, 10-30 
cells per experiment). Both patient cell lines escaped mitotic arrest within one hour. 
(e-g) Immunofluorescence labelling (e) and quantification (f-g) of indicated proteins in 
nocodazole-arrested control or patient lymphoblasts. Each dot represents one cell, with dots 
from separate experiments in different shades of grey. The red bar depicts the mean of four 
experiments ±SEM, >70 cells in total. P-values ≤ 0.05, from unpaired Student’s t-tests, are 
shown. Patient 1 cells have reduced kinetochore levels of MAD2, but not MAD1, compared to 
the controls. 
Key: patient 1, ID_0644; patient 2, ID_7054; SEM, standard error of the mean 
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Figure 2: SAC deficiency and CIN caused by TRIP13 loss-of-function is rescued with wild 
type TRIP13 
(a) Quantification of chromosome segregation errors of TRIP13-mutated patient lymphoblasts 
expressing H2B-mNeon or co-expressing LAP-TRIP13 wt. Each bar depicts the mean of 3-4 
experiments ±SEM, >85 cells in total. P-values ≤ 0.05 from an unpaired Student’s t-test are 
shown. Addition of LAP-TRIP13 wt to patient 1 cells reduced the rate of chromosome 
missegregation. 
(b) Analysis of mitotic delay as in (Fig 1d) of nocodazole-treated patient lymphoblasts 
expressing H2B-mNeon or co-expressing GFP-TRIP13 wt. Mean of three experiments ±SEM, 
>35 cells in total. Patient 1 cells expressing GFP-TRIP13 now maintain mitotic arrest. 
(c) Analysis of mitotic delay as in (Fig 1d) and (b) of nocodazole-treated HCT116 wt or HCT116 
TRIP13 KO cells expressing H2B-mNeon, co-expressing GFP-TRIP13 wt, or co-expressing 
TRIP13 p.Arg354X. Mean of three experiments ± SEM, >45 cells in total. HCT116 wt and 
TRIP13 KO + TRIP13 wt cells both maintain mitotic arrest unlike TRIP13 KO and TRIP13 KO + 
TRIP13 p.Arg354X cells. 
Key: patient 1, ID_0644; wt, wild-type; KO, knockout; CIN, chromosomal instability; SAC, spindle 
assembly checkpoint; SEM, standard error of the mean 
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Figure 3: Patient cells with TRIP13 or BUB1B mutations have severely compromised SAC 
Analysis of mitotic delay as in Fig 1d and Fig 2b of nocodazole-treated MVA patient 
lymphoblasts treated with far-red DNA dye to visualize the DNA, showing the cumulative 
percentage of cells that exited from mitosis as a function of time (mean of three experiments 
±SEM, 20 cells per experiment). Only TRIP13-mutant or BUB1B-mutant patient cells rapidly 
escape from mitotic arrest. 
Key: SAC, spindle assembly checkpoint; SEM, standard error of the mean  
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Table 1 Summary of molecular and clinical findings in individuals with biallelic 
TRIP13 mutations  
 
ID TRIP13  
mutations  
Aneuploidy Premature 
chromatid 
separation 
Wilms tumor 
age at 
diagnosis 
Current status Other clinical features 
ID_0319 c.1060C>T_p.Arg354X  
c.1060C>T_p.Arg354X 
yes  uk  2 yrs alive, 6 yrs microcephaly, developmental 
delay, growth retardation 
arthrogryposis,  
ID_0644 c.1060C>T_p.Arg354X  
c.1060C>T_p.Arg354X 
yes  yes 4 yrs,  
relapse 5 yrs 
alive, 43 yrs growth retardation 
ID_7054 c.1060C>T_p.Arg354X 
c.1060C>T_p.Arg354X  
yes  yes 2 yrs  alive, 5 yrs café au lait patches 
ID_0649 c.1060C>T_p.Arg354X 
c.1060C>T_p.Arg354X  
no yes 2 yrs  
relapse 10 yrs 
died, 10 yrs microcephaly, growth retardation, 
seizures, skin pigmentation 
ID_6112 c.1060C>T_p.Arg354X  
c.1060C>T_p.Arg354X 
uk uk 5 yrs alive, 6 yrs  
ID_7679 c.673-1G>C 
c.693-1G>C 
no  uk 1.3 yrs alive, 1.5 yrs seizures, developmental delay  
Fuller details are provided in Supplementary Fig 1.  
 
 
 
